Compare ALKS & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKS | EHC |
|---|---|---|
| Founded | 1987 | 1983 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 10.1B |
| IPO Year | 2012 | 1994 |
| Metric | ALKS | EHC |
|---|---|---|
| Price | $52.72 | $111.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $43.43 | ★ $143.29 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | N/A | ★ 24.22 |
| EPS | N/A | ★ 1.93 |
| Revenue | ★ $1,475,899,000.00 | N/A |
| Revenue This Year | $24.26 | $9.33 |
| Revenue Next Year | $4.47 | $8.14 |
| P/E Ratio | ★ N/A | $58.37 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.17 | $92.77 |
| 52 Week High | $55.67 | $127.99 |
| Indicator | ALKS | EHC |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 62.82 |
| Support Level | $27.78 | $111.08 |
| Resistance Level | $55.67 | $116.60 |
| Average True Range (ATR) | 1.72 | 2.88 |
| MACD | -0.61 | 0.51 |
| Stochastic Oscillator | 39.15 | 77.72 |
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.